China (Mainland)
lamivudine API in stock Chinese supplier 134678-17-4 cheap CAS NO.134678-17-4
- Min.Order: 1 Kilogram
- Payment Terms: L/C,D/A,D/P,T/T,Other
- Product Details
Keywords
- lamivudine API in stock
- Lamivudine Chinese supplier
- 134678-17-4 cheap lamivudine
Quick Details
- ProName: lamivudine API in stock Chinese suppli...
- CasNo: 134678-17-4
- Molecular Formula: C8H11N3O3S
- Appearance: White or almost white crystalline soli...
- Application: HIV, HBV
- DeliveryTime: 10 days after ordering
- PackAge: Two-layer LDPE bag and All Paper Drum
- Port: Any port in China
- ProductionCapacity: 500 Metric Ton/Year
- Purity: 98.0%~102.0%
- Storage: Below 30°C.
- Transportation: as per request
- LimitNum: 1 Kilogram
- Grade: Pharma Grade
Superiority
lamivudine API in stock
Chinese supplier
134678-17-4 cheap
Product use
Lamivudine is an antiviral drug used in the treatment of hepatobiliary diseases caused by hepatitis B virus infection
Lamivudine, which has been on the market for 10 years, is known as Lamivudine and chemically as 2 '3' -dideoxy-3 '-thiocytidine, or 3-TC. The product that went on sale in China was called Hoptin. Domestic and foreign randomized controlled clinical trials showed that oral administration of 100 mg per day could significantly inhibit HBV DNA level, and the serum conversion rate of HBeAg increased with the prolonged treatment time. The serum conversion rates of HBeAg were 22%, 29%, 40%, 47% and 50% after 1, 2, 3, 4 and 5 years of treatment for hBeAG-positive patients [1-3]. The serological conversion rate of HBeAg was generally higher in patients with higher ALT level before treatment [56-60]. Long-term treatment can reduce inflammation and reduce the incidence of liver fibrosis and cirrhosis [1,2]. Randomized controlled clinical trials have shown that this drug can reduce the incidence of liver decompensation and HCC (hepatocellular carcinoma) [21]. Patients with decompensated cirrhosis can also improve liver function and prolong survival [61-63]. Foreign studies have shown that lamivudine has similar efficacy and good safety in the treatment of chronic hepatitis b in children as in adults [64,65].
Lamivudine was used before liver transplantation for hepatitis B patients. After transplantation, lamivudine combined with HBIG can significantly reduce HBV re-infection after liver transplantation and reduce HBIG dose.
Lamivudine is a nucleoside analogue, and nucleotides are the raw material for the synthesis of the body's genetic material, DNA and RNA (which are essentially long strings of nucleotides held together). Nucleoside analogues mimic the structure of nucleotides structurally, but do not have the function of nucleotides. Thus, nucleoside analogues can be added to DNA synthesis, but not to the synthesis of functional nucleic acid chains, thus ending the replication of the virus. Lamivudine, which mimics a cytosine structure different from that of the natural human cytosine, works only on viruses and has no side effects in humans.
Lamivudine, as a new nucleoside analogue, is widely accepted by doctors and patients. Lamivudine is a representative nucleoside analogue with good curative effect in clinical application. Its mechanism of action is to inhibit the activity of viral DNA polymerase and reverse transcriptase, and to have a competitive inhibitory effect on the synthesis and extension of viral DNA chain
Details
[What kind of patients are suitable for lamivudine]
Lamivudine is not suitable for all hepatitis B patients.
According to the functional characteristics of Lamivudine and clinical summary of lamivudine application experience,
Lamivudine should be applied in the following cases:
(1) Moderately positive HBVDNA quantitative detection; HBeAg positive; Increase ALT by 2 to 10 times.
(2)HBeAg was negative, but HBVDNA was moderately positive (quantitative determination should be made instead of qualitative PCR results), and ALT was increased 2-10 times. Most of this is probably a mutation in the pre-C region of the virus gene.
Lamivudine is not suitable for use in the following cases:
(1)HBVDNA negative or quantitative detection <105copies/ml;
(2) Normal ALT (mainly refers to asymptomatic carriers of the virus); Patients who have had elevated ALT in the past, but now have normal ALT and AST, can be left untreated until the elevated ALT is treated. This is not because lamivudine is harmful to these patients, but because lamivudine is less effective for these patients, contrary to the principles of pharmacoeconomics.
Lamivudine, like other drugs, benefits most patients when used appropriately, does not produce the desired effect, and may even worsen the disease if not used properly.